Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission

Autor:	Sebastian Theurich, Jens M. Chemnitz, Geothy Chakupurakal, Kerstin Wennhold, Joke Malcher, Christof Scheid, Udo Holtick, Deniz Kahraman, Andreas Engert, Michael Hallek, Carsten Kobe, Michael von Bergwelt-Baildon, Alexander Shimabukuro-Vornhagen, Anke Krause
Rok vydání:	2012
Předmět:	Oncology CD4-Positive T-Lymphocytes Cancer Research medicine.medical_specialty Immunoconjugates medicine.medical_treatment Lymphocyte T-Lymphocytes Early Relapse Graft vs Host Disease Ki-1 Antigen Antineoplastic Agents Apoptosis Immunotherapy Adoptive Drug Administration Schedule Polyneuropathies Immunity Recurrence Internal medicine HLA-A2 Antigen Medicine Combined Modality Therapy Humans Transplantation Homologous Lymphocytes Brentuximab vedotin Brentuximab Vedotin business.industry Remission Induction Hematopoietic Stem Cell Transplantation Immunotherapy Hodgkin Disease Shock Septic Thrombocytopenia Transplantation medicine.anatomical_structure Treatment Outcome Immunology Th17 Cells Stem cell business medicine.drug NK Cell Lectin-Like Receptor Subfamily B T-Lymphocytes Cytotoxic
Zdroj:	Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(5)
ISSN:	1527-7755
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::361b32d32f7cdb72bd9b759d1258dc04 https://pubmed.ncbi.nlm.nih.gov/23269992 Zobrazit plný text záznamu